{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:08:57Z","timestamp":1791925737553,"version":"4.3.4"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Council of Science &amp; Technology (NST) grant by the Korean government (MSIT)","award":["CAP-20-01-KRIBB"],"award-info":[{"award-number":["CAP-20-01-KRIBB"]}]},{"name":"National Research Council of Science &amp; Technology (NST) grant by the Korean government (MSIT)","award":["2E32212"],"award-info":[{"award-number":["2E32212"]}]},{"name":"National Research Council of Science &amp; Technology (NST) grant by the Korean government (MSIT)","award":["2019H1D3A1A0107088214"],"award-info":[{"award-number":["2019H1D3A1A0107088214"]}]},{"name":"National Research Council of Science &amp; Technology (NST) grant by the Korean government (MSIT)","award":["RSPD2023R628"],"award-info":[{"award-number":["RSPD2023R628"]}]},{"name":"Institutional Program grant by the Korea Institute of Science and Technology","award":["CAP-20-01-KRIBB"],"award-info":[{"award-number":["CAP-20-01-KRIBB"]}]},{"name":"Institutional Program grant by the Korea Institute of Science and Technology","award":["2E32212"],"award-info":[{"award-number":["2E32212"]}]},{"name":"Institutional Program grant by the Korea Institute of Science and Technology","award":["2019H1D3A1A0107088214"],"award-info":[{"award-number":["2019H1D3A1A0107088214"]}]},{"name":"Institutional Program grant by the Korea Institute of Science and Technology","award":["RSPD2023R628"],"award-info":[{"award-number":["RSPD2023R628"]}]},{"name":"Korea Research Fellowship Program","award":["CAP-20-01-KRIBB"],"award-info":[{"award-number":["CAP-20-01-KRIBB"]}]},{"name":"Korea Research Fellowship Program","award":["2E32212"],"award-info":[{"award-number":["2E32212"]}]},{"name":"Korea Research Fellowship Program","award":["2019H1D3A1A0107088214"],"award-info":[{"award-number":["2019H1D3A1A0107088214"]}]},{"name":"Korea Research Fellowship Program","award":["RSPD2023R628"],"award-info":[{"award-number":["RSPD2023R628"]}]},{"name":"Researchers Supporting Project","award":["CAP-20-01-KRIBB"],"award-info":[{"award-number":["CAP-20-01-KRIBB"]}]},{"name":"Researchers Supporting Project","award":["2E32212"],"award-info":[{"award-number":["2E32212"]}]},{"name":"Researchers Supporting Project","award":["2019H1D3A1A0107088214"],"award-info":[{"award-number":["2019H1D3A1A0107088214"]}]},{"name":"Researchers Supporting Project","award":["RSPD2023R628"],"award-info":[{"award-number":["RSPD2023R628"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The emergence of cancer resistance to targeted therapy represents a significant challenge in cancer treatment. Therefore, identifying new anticancer candidates, particularly those addressing oncogenic mutants, is an urgent medical demand. A campaign of structural modifications has been conducted to further optimize our previously reported 2-anilinoquinoline-diarylamides conjugate VII as a B-RAFV600E\/C-RAF inhibitor. Considering the incorporation of a methylene bridge between the terminal phenyl and cyclic diamine, focused quinoline-based arylamides have been tailored, synthesized, and biologically evaluated. Among them, the 5\/6-hydroxyquinolines 17b and 18a stood out as the most potent members, with IC50 values of 0.128 \u00b5M, 0.114 \u00b5M against B-RAFV600E, and 0.0653 \u00b5M, 0.0676 \u00b5M against C-RAF. Most importantly, 17b elicited remarkable inhibitory potency against the clinically resistant B-RAFV600K mutant with an IC50 value of 0.0616 \u00b5M. The putative binding mode of 17b and 18a were studied by molecular docking and molecular dynamics (MD). Moreover, the antiproliferative activity of all target compounds has been examined over a panel of NCI-60 human cancer cell lines. In agreement with cell-free assays, the designed compounds exerted superior anticancer impact over the lead quinoline VII against all cell lines at a 10 \u00b5M dose. Notably, both 17b and 18b showed highly potent antiproliferative activity against melanoma cell lines with growth percent under \u221290% (SK-MEL-29, SK-MEL-5, and UACC-62) at a single dose, while 17b maintained potency with GI50 values of 1.60\u20131.89 \u00b5M against melanoma cell lines. Taken together, 17b, a promising B-RAFV600E\/V600K and C-RAF kinase inhibitor, may serve as a valuable candidate in the arsenal of anticancer chemotherapeutics.<\/jats:p>","DOI":"10.3390\/ijms24043216","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T01:56:48Z","timestamp":1675735008000},"page":"3216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Discovery of New Quinoline-Based Diarylamides as Potent B-RAFV600E\/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-8773","authenticated-orcid":false,"given":"Hyun","family":"Kim","sequence":"first","affiliation":[{"name":"Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung","family":"Park","sequence":"additional","affiliation":[{"name":"Supercomputing Application Center, Division of National Supercomputing, Korea Institute of Science and Technology Information, Daejeon 34141, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjae","family":"Seo","sequence":"additional","affiliation":[{"name":"Supercomputing Application Center, Division of National Supercomputing, Korea Institute of Science and Technology Information, Daejeon 34141, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6064-7680","authenticated-orcid":false,"given":"Kwang-Hwi","family":"Cho","sequence":"additional","affiliation":[{"name":"School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0483-8113","authenticated-orcid":false,"given":"Mohammed","family":"Alanazi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11421, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kyoung","family":"Bang","sequence":"additional","affiliation":[{"name":"Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-8022","authenticated-orcid":false,"given":"Gyochang","family":"Keum","sequence":"additional","affiliation":[{"name":"Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea"},{"name":"Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul 02792, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"El-Damasy","sequence":"additional","affiliation":[{"name":"Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"ref_1","first-page":"519","article-title":"Provisional Mortality Data\u2014United States, 2020","volume":"70","author":"Ahmad","year":"2021","journal-title":"MMWR Surveill. Summ."},{"key":"ref_2","unstructured":"(2022, November 30). World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_3","first-page":"101","article-title":"Tyrosine Kinase\u2014Role and Significance in Cancer","volume":"1","author":"Paul","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein Kinases\u2014The Major Drug Targets of the Twenty-First Century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","first-page":"452","article-title":"B-Raf Kinase Inhibitors for Cancer Treatment","volume":"8","author":"Li","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.bbamcr.2007.05.001","article-title":"Raf Kinases: Function, Regulation and Role in Human Cancer","volume":"1773","author":"Leicht","year":"2007","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_7","first-page":"3","article-title":"Targeting the Raf Kinases in Human Cancer: The Raf Dimer Dilemma","volume":"118","author":"Durrant","year":"2017","journal-title":"Nat. Publ. Gr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11493","DOI":"10.1158\/0008-5472.CAN-05-2211","article-title":"Expression of Endogenous Oncogenic V600EB-Raf Induces Proliferation and Developmental Defects in Mice and Transformation of Primary Fibroblasts","volume":"65","author":"Mercer","year":"2005","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF Gene in Human Cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CMR.0000000000000388","article-title":"Putative Genomic Characteristics of BRAF V600K versus V600E Cutaneous Melanoma","volume":"27","author":"Li","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nepote, A., Avallone, G., Ribero, S., Cavallo, F., Roccuzzo, G., Mastorino, L., Conforti, C., Paruzzo, L., Poletto, S., and Schianca, F.C. (2022). Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030828"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00132-17","DOI":"10.1128\/MCB.00132-17","article-title":"Phosphorylation of the C-Raf N Region Promotes Raf Dimerization","volume":"37","author":"Takahashi","year":"2017","journal-title":"Mol. Cell. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3109\/10409238.2015.1102858","article-title":"A-Raf: A New Star of the Family of Raf Kinases","volume":"50","author":"An","year":"2015","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105597","DOI":"10.1016\/j.bioorg.2022.105597","article-title":"Recent Advances in B-RAF Inhibitors as Anticancer Agents","volume":"120","author":"Khan","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1021\/jm400778d","article-title":"Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C -7-Substituted 1,3-Benzothiazole Derivatives","volume":"56","author":"Okaniwa","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bmcl.2019.01.003","article-title":"Design, Synthesis, and In Vitro Evaluation of N-(3-(3-Alkyl-1H-Pyrazol-5-Yl) Phenyl)-Aryl Amide for Selective RAF Inhibition","volume":"29","author":"Jung","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s00044-017-1957-z","article-title":"Synthesis and Biological Evaluation of Novel N-(5-Phenyl-1H-Pyrazol-3-Yl)Benzenesulfonamide Derivatives as Potential BRAFV600E Inhibitors","volume":"26","author":"Gong","year":"2017","journal-title":"Med. Chem. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","first-page":"B260","article-title":"Preclinical Characterization of BAY 73-4506: A Kinase Inhibitor with Broad Spectrum Antitumor Activity Targeting Oncogenic and Angiogenic Kinases","volume":"6","author":"Wilhelm","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14737140.2018.1527688","article-title":"A Comprehensive Review of Protein Kinase Inhibitors for Cancer Therapy","volume":"18","author":"Kannaiyan","year":"2018","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2147\/CMAR.S170105","article-title":"Development of Small-Molecule Therapeutics and Strategies for Targeting RAF Kinase in BRAF-Mutant Colorectal Cancer","volume":"10","author":"Pan","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: The First Drug Approved for BRAF-Mutant Cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/ml4000063","article-title":"Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors","volume":"4","author":"Rheault","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1021\/acs.jmedchem.0c02085","article-title":"Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-Quinazolinone Aryl Urea Pan-RAF Kinase Inhibitor","volume":"64","author":"Huestis","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9081","DOI":"10.2147\/OTT.S171693","article-title":"Encorafenib\/Binimetinib for the Treatment of BRAF-Mutant Advanced, Unresectable, or Metastatic Melanoma: Design, Development, and Potential Place in Therapy","volume":"11","author":"Sun","year":"2018","journal-title":"Onco. Targets. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and Binimetinib: First Global Approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1021\/jm901808w","article-title":"A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I \u201cGatekeeper\u201d Mutant of Bcr-Abl","volume":"53","author":"Choi","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbrc.2020.07.110","article-title":"The First Small Molecules Capable of Strongly Suppressing Proliferation of Cancer Cells Harboring BRAF Class I\/II\/III Mutations","volume":"532","author":"Choi","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2014.11.008","article-title":"Design, Synthesis and Evaluation of Novel 2-(1H-Imidazol-2-Yl) Pyridine Sorafenib Derivatives as Potential BRAF Inhibitors and Anti-Tumor Agents","volume":"90","author":"Jiao","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1039\/C7OB00518K","article-title":"Rational Design, Synthesis, and Biological Evaluation of Pan-Raf Inhibitors to Overcome Resistance","volume":"15","author":"Wang","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1021\/jm500007h","article-title":"Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib","volume":"57","author":"Cheng","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1021\/acs.jmedchem.5b00270","article-title":"Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-Pyrazolo [3,4-d]Pyrimidin-4-Amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer","volume":"58","author":"Zhang","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejmech.2014.09.068","article-title":"A New Series of Diarylamides Possessing Quinoline Nucleus: Synthesis, In Vitro Anticancer Activities, and Kinase Inhibitory Effect","volume":"87","author":"Khan","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"112756","DOI":"10.1016\/j.ejmech.2020.112756","article-title":"2-Anilinoquinoline Based Arylamides as Broad Spectrum Anticancer Agents with B-RAFV600E\/C-RAF Kinase Inhibitory Effects: Design, Synthesis, In Vitro Cell-Based and Oncogenic Kinase Assessments","volume":"208","author":"Haque","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejmech.2016.02.039","article-title":"Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-RafV600E and C-Raf kinase inhibitory activities","volume":"115","author":"Lee","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1016\/j.bmcl.2016.05.047","article-title":"Novel 5-Substituted-2-Anilinoquinolines with 3-(Morpholino or 4-Methylpiperazin-1-Yl)Propoxy Moiety as Broad Spectrum Antiproliferative Agents: Synthesis, Cell Based Assays and Kinase Screening","volume":"26","author":"Cho","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cbdd.12836","article-title":"Design and Synthesis of New 2-Anilinoquinolines Bearing N-Methylpicolinamide Moiety as Potential Antiproliferative Agents","volume":"89","author":"Seo","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_39","unstructured":"Yasri, A., Cheve, G., Bories, C., and Delon, L. (2010). Derivatives of Azaindoles as Inhibitors of Protein Kinase ABL and SRC. (WO2010092489A1), WIPO (PCT)."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1039\/C5OB00037H","article-title":"Design, Synthesis and Biological Evaluation of 1-Phenanthryl-Tetrahydroisoquinoline Derivatives as Novel P21-Activated Kinase 4 (PAK4) Inhibitors","volume":"13","author":"Song","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ejmech.2015.07.025","article-title":"Design, Synthesis, in-Vitro Antiproliferative Activity and Kinase Profile of New Picolinamide Based 2-Amido and Ureido Quinoline Derivatives","volume":"101","author":"Seo","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/ejoc.200700044","article-title":"Reaction of Isocyanate-Functionalised Silicon Wafers with Complex Amino Compounds","volume":"2007","author":"Perzyna","year":"2007","journal-title":"Eur. J. Org. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"104121","DOI":"10.1016\/j.bioorg.2020.104121","article-title":"Diarylurea Derivatives Comprising 2,4-Diarylpyrimidines: Discovery of Novel Potential Anticancer Agents via Combined Failed-Ligands Repurposing and Molecular Hybridization Approaches","volume":"103","author":"Farag","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/acs.oprd.5b00417","article-title":"NMR Chemical Shifts of Trace Impurities: Industrially Preferred Solvents Used in Process and Green Chemistry","volume":"20","author":"Babij","year":"2016","journal-title":"Org. Process Res. Dev."},{"key":"ref_46","unstructured":"(2022, November 30). Reaction Biology Corporation. Available online: http:\/\/www.reactionbiology.com\/webapps\/site\/Kinase_Assay_Protocol.aspx."},{"key":"ref_47","unstructured":"(2022, November 30). DTP Human Tumor Cell Line Screen Process, Available online: https:\/\/dtp.cancer.gov\/discovery_development\/nci-60\/methodology.htm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/jcc.10416","article-title":"A Kinematic View of Loop Closure","volume":"25","author":"Coutsias","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM Simulations Using the CHARMM36 Additive Force Field","volume":"12","author":"Lee","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/wcms.1121","article-title":"An Overview of the Amber Biomolecular Simulation Package","volume":"3","author":"Case","year":"2013","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","article-title":"Ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution","volume":"16","author":"Tian","year":"2020","journal-title":"J. Chem. Theory Comput."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and Testing of a General Amber Force Field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle Mesh Ewald: An N log(N) Method for Ewald Sums in Large Systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10822-021-00389-3","article-title":"Improving virtual screening results with mm\/gbsa and mm\/pbsa rescoring","volume":"35","author":"Sahakyan","year":"2021","journal-title":"J. Comput. Aided Mol. Des."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:25:51Z","timestamp":1760120751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043216"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043216","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]}}}